EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential

Karolina Łuczkowska iD, Piotr Kulig iD, Klaudia Rusińska, Bartłomiej Baumert iD, Bogusław Machaliński

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242316780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Karolina Łuczkowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Multiple Myeloma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education, Minister of Science and Higher Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a plasma cell malignancy that accounts for 1% of all cancers and is the second-most-common hematological neoplasm. Bortezomib (BTZ) is a proteasome inhibitor widely implemented in the treatment of MM alone or in combination with other agents. The development of resistance to chemotherapy is one of the greatest challenges of modern oncology. Therefore, it is crucial to discover and implement new adjuvant therapies that can bypass therapeutic resistance. In this paper, we investigated the in vitro effect of methylation inhibitor 5-Aza-2′-deoxycytidine on the proliferative potential of MM cells and the development of resistance to BTZ. We demonstrate that alterations in the DNA methylation profile are associated with BTZ resistance. Moreover, the addition of methylation inhibitor 5-Aza-2′-deoxycytidine to BTZ-resistant MM cells led to a reduction in the proliferation of the BTZ-resistant phenotype, resulting in the restoration of sensitivity to BTZ. However, further in vitro and ex vivo studies are required before adjuvant therapy can be incorporated into existing treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMultiple MyelomaHumansBortezomibDecitabineDrug Resistance, NeoplasmCell Line, TumorMethylationApoptosis

Stichwörter der Autor:innen

5-Aza-2′-deoxycytidinebortezomibmethylation inhibitormultiple myelomaresistance

Substanzen

BortezomibDecitabineAntineoplastic Agents

Autor:innen und Institutionen

  • Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Department of Hematology and Transplantology, Pomeranian Medical University, 71-252 Szczecin, Poland.

ORCID-Profile: Karolina Łuczkowska, Piotr Kulig, Bartłomiej Baumert

Förderung

  • Ministry of Science and Higher Education
  • Minister of Science and Higher Education

Zitieren

APA

Łuczkowska, K., Kulig, P., Rusińska, K., Baumert, B., & Machaliński, B. (2023). 5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316780

Vancouver

Łuczkowska K, Kulig P, Rusińska K, Baumert B, Machaliński B. 5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316780

BibTeX
@article{uczkowska2023,
  author = {Łuczkowska, Karolina and Kulig, Piotr and Rusińska, Klaudia and Baumert, Bartłomiej and Machaliński, Bogusław},
  title = {5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242316780}
}
Kostenlos starten →